Risk of venous and arterial thromboembolism associated with thrombophilic defects and antiphospholipid antibodies
. | . | Venous thromboembolism . | . | . | Arterial thromboembolism . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abnormality . | Patients, n . | Events, n . | Observation period, total y . | Annual incidence, % (95% CI) . | Events, n . | Observation period, total y . | Annual incidence (95% CI) . | ||||
| No abnormality | 80 | 6 | 1030 | 0.58 (0.21-1.27) | 8 | 1006 | 0.80 (0.34-1.57) | ||||
| Lupus anticoagulant | 11 | 4 | 164 | 2.43 (0.66-6.23) | 3 | 203 | 1.48 (0.30-4.32) | ||||
| Anticardiolipin antibodies | 12 | 3 | 186 | 1.62 (0.33-4.72) | 4 | 208 | 1.93 (0.53-4.94) | ||||
| Antithrombin deficiency | 5 | 1 | 79 | 1.27 (0.03-7.09) | 1 | 92 | 1.09 (0.03-6.1) | ||||
| Protein C deficiency (type I or II) | 1 | 0 | 22 | 0 (0-16.59) | 0 | 22 | 0 (0-16.59) | ||||
| Protein S deficiency (type I) | 4 | 0 | 58 | 0 (0-6.40) | 0 | 58 | 0 (0-6.40) | ||||
| Plasminogen deficiency | 1 | 0 | 22 | 0 (0-16.59) | 0 | 22 | 0 (0-16.59) | ||||
| APC resistance | 49 | 6 | 652 | 0.92 (0.34-2.00) | 5 | 692 | 0.72 (0.23-1.69) | ||||
| Factor V Leiden | 11 | 3 | 142 | 2.12 (0.44-6.20) | 0 | 161 | 0 (0-2.29) | ||||
| Prothrombin G20210A | 2 | 2 | 4 | 51.3 (6.21-185.3) | 0 | 39 | 0 (0-9.54) | ||||
. | . | Venous thromboembolism . | . | . | Arterial thromboembolism . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abnormality . | Patients, n . | Events, n . | Observation period, total y . | Annual incidence, % (95% CI) . | Events, n . | Observation period, total y . | Annual incidence (95% CI) . | ||||
| No abnormality | 80 | 6 | 1030 | 0.58 (0.21-1.27) | 8 | 1006 | 0.80 (0.34-1.57) | ||||
| Lupus anticoagulant | 11 | 4 | 164 | 2.43 (0.66-6.23) | 3 | 203 | 1.48 (0.30-4.32) | ||||
| Anticardiolipin antibodies | 12 | 3 | 186 | 1.62 (0.33-4.72) | 4 | 208 | 1.93 (0.53-4.94) | ||||
| Antithrombin deficiency | 5 | 1 | 79 | 1.27 (0.03-7.09) | 1 | 92 | 1.09 (0.03-6.1) | ||||
| Protein C deficiency (type I or II) | 1 | 0 | 22 | 0 (0-16.59) | 0 | 22 | 0 (0-16.59) | ||||
| Protein S deficiency (type I) | 4 | 0 | 58 | 0 (0-6.40) | 0 | 58 | 0 (0-6.40) | ||||
| Plasminogen deficiency | 1 | 0 | 22 | 0 (0-16.59) | 0 | 22 | 0 (0-16.59) | ||||
| APC resistance | 49 | 6 | 652 | 0.92 (0.34-2.00) | 5 | 692 | 0.72 (0.23-1.69) | ||||
| Factor V Leiden | 11 | 3 | 142 | 2.12 (0.44-6.20) | 0 | 161 | 0 (0-2.29) | ||||
| Prothrombin G20210A | 2 | 2 | 4 | 51.3 (6.21-185.3) | 0 | 39 | 0 (0-9.54) | ||||
Protein S deficiency type III was excluded because it was not tested in all patients.